Table 3.
Adjusted odds ratios and 95% confidence intervals for the associations between tumor clinicopathological features and subtypes of breast cancer re-classified based on p53 expression
| Characteristic | A-like | B-like/HER2− | B-like/HER2+ | HER2-enriched | TNBC | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| p53+ vs. p53− | p53+ vs. p53− | p53+ vs. p53− | p53+ vs. p53− | p53+ vs. p53− | ||||||
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |
| Age (years) | ||||||||||
| <40 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||||
| 40–50 | 1.13 (0.88, 1.46) | 0.32 | 0.92 (0.62, 1.39) | 0.71 | 1.25 (0.83, 1.88) | 0.28 | 1.67 (0.90, 3.10) | 0.10 | 0.91 (0.56, 1.48) | 0.72 |
| 50–60 | 0.88 (0.67, 1.15) | 0.36 | 0.94 (0.63, 1.40) | 0.76 | 1.25 (0.83, 1.89) | 0.29 | 2.16 (1.20, 3.90) | 0.01 | 1.13 (0.70, 1.85) | 0.61 |
| 60–70 | 0.85 (0.64, 1.13) | 0.27 | 1.08 (0.69, 1.70) | 0.72 | 1.32 (0.79, 2.20) | 0.28 | 2.00 (0.98, 4.09) | 0.06 | 1.32 (0.74, 2.34) | 0.35 |
| 70+ | 0.74 (0.52, 1.06) | 0.11 | 0.99 (0.55, 1.81) | 0.98 | 1.11 (0.54, 2.25) | 0.78 | 2.08 (0.74, 5.82) | 0.16 | 0.65 (0.33, 1.29) | 0.22 |
| P trend | <0.01 | 0.26 | 0.98 | 0.03 | ||||||
| Histologic grade* | ||||||||||
| Well diff. | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | ||||||
| Mod. diff. | 1.40 (1.10, 1.77) | <0.01 | 4.79 (0.98, 23.52) | 0.05 | 0.33 (0.07, 1.61) | 0.17 | 1.00 (reference) | 0.26 (0.02, 3.08) | 0.29 | |
| Poorly diff. | NE | 5.33 (1.09, 25.99) | 0.03 | 0.34 (0.07, 1.66) | 0.18 | 1.18 (0.78, 1.77) | 0.42 | 1.15 (0.80, 1.64) | 0.46 | |
| Tumor size | ||||||||||
| <2 cm | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||||
| 2–5 cm | 0.99 (0.78, 1.24) | 0.92 | 1.10 (0.75, 1.62) | 0.61 | 0.92 (0.60, 1.42) | 0.71 | 1.37 (0.74, 2.54) | 0.31 | 1.10 (0.71, 1.68) | 0.67 |
| >5 cm | 0.96 (0.47, 1.96) | 0.92 | 2.91 (0.98, 8.65) | 0.05 | 3.12 (0.62, 15.66) | 0.17 | 0.32 (0.07, 1.43) | 0.13 | 0.95 (0.32, 2.77) | 0.93 |
| P trend | 0.84 | 0.08 | 0.87 | 0.90 | ||||||
| Lymph nodes | ||||||||||
| 0 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||||
| 1–3 | 0.95 (0.80, 1.12) | 0.56 | 1.00 (0.75, 1.34) | 0.99 | 0.92 (0.67, 1.27) | 0.62 | 0.80 (0.51, 1.26) | 0.34 | 0.74 (0.52, 1.05) | 0.09 |
| >3 | 1.09 (0.89, 1.34) | 0.38 | 0.98 (0.72, 1.33) | 0.89 | 0.95 (0.68, 1.32) | 0.75 | 0.89 (0.56, 1.40) | 0.61 | 0.81 (0.54, 1.05) | 0.30 |
| KI67 (%) | ||||||||||
| Q1 (<10) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||||
| Q2 (10–20) | 1.33 (1.09, 1.63) | <0.01 | 1.37 (0.83, 2.26) | 0.22 | 1.37 (0.77, 2.43) | 0.28 | 1.68 (0.67, 4.22) | 0.27 | 1.04 (0.43, 2.52) | 0.92 |
| Q3 (20–35) | 1.81 (1.48, 2.21) | <0.01 | 2.09 (1.32, 3.32) | <0.01 | 1.46 (0.87, 2.45) | 0.16 | 2.09 (0.91, 4.80) | 0.08 | 0.51 (0.23, 1.14) | 0.10 |
| Q4 (>35) | 2.43 (1.84, 3.20) | <0.01 | 2.74 (1.71, 4.39) | <0.01 | 1.69 (0.98, 2.91) | 0.06 | 2.22 (0.96, 5.16) | 0.06 | 0.53 (0.24, 1.17) | 0.12 |
| P trend | <0.01 | <0.01 | 0.26 | 0.02 | ||||||
| CK5/6 status | ||||||||||
| Negative | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||||
| Positive | 1.06 (0.55, 2.03) | 0.86 | 1.74 (1.10, 2.75) | 0.02 | 1.31 (0.64, 2.68) | 0.46 | 0.78 (0.41, 1.48) | 0.45 | 1.18 (0.84, 1.66) | 0.34 |
| EGFR status | ||||||||||
| Negative | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||||
| Positive | 1.80 (1.27, 2.54) | <0.01 | 1.05 (0.73, 1.51) | 0.79 | 1.10 (0.76, 1.58) | 0.60 | 0.90 (0.54, 1.47) | 0.67 | 0.97 (0.56, 1.66) | 0.91 |
Note: Odds ratios (OR) and 95% confidence intervals (CI) were obtained from subtype-specific logistic regression models mutually adjusted for age
*Histologic grade (well differentiated (grade 1), moderately differentiated (grade 2), poorly differentiated (grade 3)), tumor size, lymph nodal involvement, KI67, CK5/6 and EGFR. NE = Not estimated since grade 3 tumors do not qualify as luminal A-like based on the criteria for subtype definition